Provenge sipuleucel-T: Phase II data

In the open-label, U.S. Phase II P-16 trial in 21 evaluable patients, Provenge plus Avastin increased median prostate specific antigen doubling time (PSADT) by >85% from 6.9 months pretreatment to 12...